Black Diamond Q3 net loss $8.5M, cash $135.5M; silevertinib Phase 2 ORR data due Q4 2025

Black Diamond Therapeutics, Inc.

2025-Q3 EPS reported $0.65 revenue$70,000,000

Cash, cash equivalents and investments $135.5M as of Sept 30, 2025; funds operations into Q4 2027.
Net loss $8.5M in Q3 2025 vs $15.6M in Q3 2024; R&D expenses fell to $7.4M from $12.9M.
ORR and preliminary duration of treatment data from silevertinib Phase 2 in 1L non-classical EGFRm NSCLC expected later this quarter.
PFS data from Phase 2 trial expected in H1 2026; company plans FDA feedback on registrational path.
Exploring partnership opportunities for silevertinib in NSCLC and glioblastoma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.